Prevalence of cancer in Parkinson's disease related to R1441G and G2019S mutations in LRRK2

Movement Disorders

Volumn 29, Issue 6, 2014, Pages 750-755

  Ruiz Martínez, Javier ^a,b,c   de la Riva, Patricia ^a   Rodríguez Oroz, Maria C ^c   Mondragón Rezola, Elisabet ^a,b   Bergareche, Alberto ^a,b,c   Gorostidi, Ana ^b,c   Gago, Belen ^b,c   Estanga, Ainara ^a   Larrañaga, Nerea ^d,e   Sarasqueta, Cristina ^c,f   López de Munain, Adolfo ^a,b,c,g   Martí Massó, José F ^a,b,c  

^a HOSPITAL DONOSTIA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^d Basque Government   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f Research Network for Health Services in Chronic Disease (REDISSEC)   (Spain)

^g UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Cancer; G2019S; LRRK2; Parkinson's disease; R1441G

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CANCER RISK; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENINGIOMA; NEOPLASM; NON MELANOMA SKIN CANCER; ONSET AGE; OVARY CANCER; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SPAIN; ADULT; ANALYSIS OF VARIANCE; GENETICS; MIDDLE AGED; NEOPLASMS; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84899966492     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25778     Document Type: Article

References (31)

1. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007;69:1542-1550.
2. Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010;21:697-707.
3. Becker C, Brobert GP, Saga Johansson S, Jick SS, Meier CR. Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord 2010;16:186-190.
4. Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, Leimpeter AD, Nelson LM. Comorbid cancer in Parkinson's disease. Mov Disord 2010;25:1809-1817.
5. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer in Parkinson's disease. J Neurol 2000;247:429-434.
6. Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort. Mov Disord 2005;30:719-725.
7. Driver JA, Logroscino G, Buring JE, Gaziano M, Kurth T. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 2007;16:1260-1265.
8. Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006;17:582-587.
9. Møller H, Mellemkjær L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995;310:1500-1501.
10. Fiala KH, Whetteckey J, Manyam BV. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence? Parkinsonism Relat Disord 2003;9:321-327.
11. Zanetti R, Loria D, Rosso S. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 2006;16:201-206.
12. Rigel DS, Patel Z, Bolognia J, Eichler C, Ellis DL, Friedman RJ. Evaluation of Parkinson's disease (PD) prevalence in patients with malignant melanoma. Mov Disord 2006;21(Suppl 13):S58.
13. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology 2009;73:1286-1291.
14. Paisan-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology 2010;75:1653-1655.
15. Cesari R, Martin ES, Calin GA, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25eq27. Proc Natl Acad Sci U S A 2003;100:5956e61.
16. Garber K. Parkinson's disease and cancer: the unexplored connection. J Natl Cancer Inst 2010;102:371-374.
17. Kim RH, Mak TW. Tumours and tremors: how PTEN regulation underlies both. Br J Cancer 2006;94:620-624.
18. Albrecht M. LRRK2 mutations and parkinsonism. Lancet 2005;365:1230.
19. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 2006;9:1231-1233.
20. Kachergus J, Mata IF, Hulihan MM et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680.
21. Saunders-Pullman R, Barrett MJ, Stanley KM, et al. LRRK2 G2019S mutations are associated with increased cancer risk in Parkinson disease. Mov Disord 2010;25:2536-2541.
22. Inzelberg R, Cohen OS, Aharon-Peretz J, et al. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology 2012;78:781-786.
23. Hassin-Baer S, Laitman Y, Azizi E, et al. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol 2009;256:483-487.
24. Strongosky AJ, Farrer M, Wszolek ZK. Are Parkinson disease patients protected from some but not all cancers? Neurology 2008;71:1650; author reply 1650-1651.
25. Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-596.
26. Gorostidi A, Ruiz-Martinez J, de Munain AL, Alzualde A, Masso JF. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009;10:157-159.
27. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
28. Mortiboys H, Cox A, Brock IW, Bandmann O. The common PARK8 mutation LRRK2 (G2019S) is not a risk factor for breast cancer in the absence of Parkinson's disease. J Neurol 2013;260:2177-2178.
29. Berthier A, Navarro S, Jiménez-Sáiz J, et al. PINK1 displays tissue-specific subcellular location and regulates apoptosis and cell growth in breast cancer cells. Hum Pathol 2011;42:73-87.
30. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-158.
31. Ruiz-Martínez J, Gorostidi A, Ibáñez B, et al. Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque Country (Spain). Mov Disord 2010;25:2340-2345.